| 16 |
Dong-A ST and its subsidiary to codevelop long-acting obesity drug with ImmunoForge
|
2024-08-20 |
1847 |
| 15 |
Dong-A ST Presents Preclinical Results of Tau-Targeting Dementia Treatment ‘DA-7503’ at AAIC
|
2024-08-08 |
2385 |
| 14 |
DA-1241 Global Phase 2 Part 1 Patient Recruitment Completed
|
2024-04-05 |
1598 |
| 13 |
Dong-A ST, STGen Bio, ST Pharm's Triangular Partnership at Songdo Bio Hub
|
2024-04-05 |
3164 |
| 12 |
IMBiologics partners with Dong-A ST for novel antibody drug development
|
2024-02-19 |
1464 |
| 11 |
Dong-A ST partners with KIST for breakthrough in inflammatory bowel disease treatment
|
2024-02-19 |
1272 |
| 10 |
Dong-A ST NeuroBo Pharmaceuticals Initiates Phase 2 Part 2 Clinical Trial for DA-1241
|
2024-02-19 |
1077 |
| 9 |
Dong-A ST Signs R&D Agreement with Eleven Therapeutics for RNA-based Gene Therapy
|
2024-01-15 |
1448 |
| 8 |
Dong-A ST acquires AbTis to develop new ADCs
|
2024-01-15 |
2260 |
| 7 |
Dong-A ST advances phase 1/2a study of cancer immunotherapy
|
2023-12-19 |
1029 |
